Neogene Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Neogene Therapeutics's estimated annual revenue is currently $35.1M per year.
- Neogene Therapeutics's estimated revenue per employee is $221,954
- Neogene Therapeutics's total funding is $125M.
Employee Data
- Neogene Therapeutics has 158 Employees.
- Neogene Therapeutics grew their employee count by 22% last year.
Neogene Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $15.3M | 14 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.5M | 29 | -6% | N/A | N/A |
#10 | $9.6M | 62 | -7% | N/A | N/A |
What Is Neogene Therapeutics?
Neogene Therapeutics is a pre-clinical stage biotechnology company aiming to change the paradigm of treatment for solid cancers. Our mission is to provide cancer patients with T cell therapies targeting mutated proteins called neo-antigens, which are present on cancer cells as a consequence of DNA mutations. Neogene is developing novel technologies to enable the engineering of ‘designer T cells' with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.
keywords:N/A$125M
Total Funding
158
Number of Employees
$35.1M
Revenue (est)
22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neogene Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | IT Compliance Consultant | Reveal Email/Phone |
2 | VP and Head Information Technology | Reveal Email/Phone |
3 | Director - Application Services & Data Analytics | Reveal Email/Phone |
4 | Senior Medical Director | Reveal Email/Phone |
5 | Sr. Director, Clinical Operations | Reveal Email/Phone |
6 | Assistant Controller | Reveal Email/Phone |
7 | Head Human Resources | Reveal Email/Phone |
8 | Sr. Director, Clinical Operations | Reveal Email/Phone |
9 | Director Quality | Reveal Email/Phone |
10 | Associate Director, CMC Program Management | Reveal Email/Phone |
Neogene Therapeutics News
... Therapeutics, Novartis, Pfizer, PokeAcel, Roche/Genentech, Sanofi, and T-Knife (paid to the institution); consultancy fees from Neogene...
Four Additional Board Members Appointed to Complement Founding Expertise NEW YORK & AMSTERDAM–(BUSINESS WIRE)–October 6, 2020– Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today ...
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised $110 million in a Series A financing. The financing was co-led by EcoR1 Capital, Jeito Capital and ...
Neogene Therapeutics Inc. has raised $110 million in venture financing and entered into the race to cure cancers through cell therapies tailored to individual patients. EcoR1 Capital, Jeito Capital and Syncona led the financing, which also included Polaris Partners, Pontifax and seed investors ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $36.5M | 158 | 34% | N/A |
#2 | $15M | 159 | 15% | N/A |
#3 | $15M | 160 | 28% | N/A |
#4 | $39M | 161 | 21% | N/A |
#5 | $35.8M | 162 | 95% | N/A |
Neogene Therapeutics Executives
Name | Title |
---|---|
Carsten Linnemann | Chief Executive Officer |
Christopher Wilfong | Chief Business Officer |
Brent Pfeiffenberger | Chief Operating Officer |
Han Lee | Chief Financial Officer |
Raphael Rousseau | Chief Medical Officer |
Han Lee | Chief Financial Officer |
Samuel Rodman | Chief Executive Officer & Co-Founder |
Raphaël Rousseau | Chief Medical Officer |
Martine Serné | Executive Assistant To Chief Executive Officer |
Brent Pfeiffenberger | Chief Operating Officer |
Gavin Bendle | Vice President R&D |
Kanti Thirumoorthy | SVP, Technical Operations |
Mauro Avanzi | Vice President, Clinical Development, Neogene Therapeutics |
David Lund | Vice President, Intellectual Property |
Marianna Sabatino | Vice President, Head of Process Development and TCR Selection Facility Site Head |
Arianne Garcia | Vice President of Translational Sciences |
David Lund | VP, Intellectual Property |
Marisa Leonard | Vice President, Head of Business Development |
Harish Mundre | Vice President, Head of Information Technology |
Sanne Weijzen | Vice President, Corporate Strategy and EU Operations |